0000000000970872

AUTHOR

Wedemeyer Heiner

showing 2 related works from this author

Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-…

2020

The impact of direct-acting antiviral (DAA) therapies on fibrosis regression remains uncertain. In the current study, we prospectively evaluated dynamics of liver stiffness by transient elastography (TE) in patients with chronic HCV infection receiving DAA-based treatment. Patients (260) were enrolled in the German Hepatitis C-Registry (DHC-R), a national multicentre real-world cohort. Liver stiffness (LS) was assessed at baseline, end of treatment (EOT) and 24 weeks after EOT (FU24) by TE. Biochemical, virological and clinical data were obtained in parallel. In patients with SVR, there was a significant improvement of LS between baseline (median [range], 8.6 [1.7-73.5] kPa) and FU24 (7.9 […

Liver Cirrhosismedicine.medical_specialtySustained Virologic ResponseBilirubinMedizinGastroenterologyAntiviral AgentsVirusTransaminase03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFibrosisVirologyInternal medicineGermanymedicineHumans030212 general & internal medicineRegistriesHepatitisHepatologybusiness.industryHepatitis CHepatitis C Chronicmedicine.diseaseInfectious DiseasesTreatment OutcomechemistryLiverCohortElasticity Imaging Techniques030211 gastroenterology & hepatologybusinessTransient elastographyJournal of viral hepatitisREFERENCES
researchProduct

The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-α2b and ribavirin in patients…

2008

Background/Aims The efficacy of pegylated interferon alpha and ribavirin in HBV/HCV co-infected patients is unknown. Methods Nineteen patients with chronic HBV/HCV co-infection (HBsAg and HCV-RNA positive; 10 HCV-genotype 1; 9 HCV-genotype 2 or 3) were included in this prospective multicenter pilot study. Baseline HBV-DNA was negative in 13 individuals. All patients received weight-adjusted PEG-IFN-α2b and ribavirin for 48 weeks. Results In the intent-to-treat analysis, a biochemical and an HCV-RNA response were observed in 12 and 14 patients, respectively (63% and 74%). At the end of the treatment as well as at the end of the follow-up the HCV-RNA response was 93% (14/15) in patients adher…

AdultMalemedicine.medical_specialtyHBsAgCombination therapyHepatitis C virusInterferon alpha-2medicine.disease_causeAntiviral AgentsGastroenterologyPolyethylene Glycolschemistry.chemical_compoundHepatitis B ChronicPegylated interferonInternal medicineRibavirinmedicineHumansProspective StudiesAdverse effectAgedHepatitis B virusHepatologybusiness.industryRibavirinInterferon-alphavirus diseasesHepatitis C ChronicMiddle AgedRecombinant Proteinsdigestive system diseaseschemistryDNA ViralImmunologyRNA ViralFemaleViral diseasebusinessmedicine.drugJournal of Hepatology
researchProduct